SCHEMBL6498615

SCHEMBL6498615

CCc1ccc(-c2ccc(Cl)cc2)c(C(=O)O)c1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 3/20 0.54
LTB4R2 Q9NPC1 3/20 0.52
HSD17B10 Q99714 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
CTRC Q99895 1/20 0.46
RAB9A P51151 2/20 0.46
SLC6A4 P31645 1/20 0.45
SLC6A3 Q01959 1/20 0.45
PTPN11 Q06124 1/20 0.45
EIF4E P06730 1/20 0.45
NPC1 O15118 1/20 0.44
PPARG P37231 2/20 0.44
LTB4R Q15722 1/20 0.44
AURKA O14965 1/20 0.44
TPX2 Q9ULW0 1/20 0.44
ALDH1A1 P00352 1/20 0.43
TP53 P04637 1/20 0.43
MARS1 P56192 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14611035 0.88 SLC6A4 (0.45) FOLH1LTB4R2SMN1; SMN2CTRCRAB9A
SCHEMBL6491569 0.86 FOLH1 (0.55) FOLH1LTB4R2HSD17B10SMN1; SMN2RAB9A
SCHEMBL3737187 0.85 FOLH1 (0.71) FOLH1LTB4R2HSD17B10SMN1; SMN2RAB9A
SCHEMBL3168574 0.84 METAP2 (0.54) FOLH1LTB4R2HSD17B10SMN1; SMN2RAB9A
SCHEMBL3823506 0.84 FOLH1 (0.54) FOLH1LTB4R2HSD17B10SMN1; SMN2RAB9A
SCHEMBL6498907 0.83 ALDH1A1 (0.61) FOLH1LTB4R2HSD17B10SMN1; SMN2RAB9A
SCHEMBL11527291 0.81 SMN1; SMN2 (0.49) LTB4R2HSD17B10SMN1; SMN2RAB9APPARG
SCHEMBL6487907 0.81 PSEN1 (0.56) FOLH1HSD17B10SMN1; SMN2RAB9APTPN11
SCHEMBL6499129 0.79 HSD17B10 (0.51) HSD17B10SMN1; SMN2RAB9AEIF4ENPC1
SCHEMBL6492999 0.78 SMN1; SMN2 (0.57) SMN1; SMN2RAB9APTPN11EIF4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 FOLH1 2079/4885LTB4R2 400/4885HSD17B10 901/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.